- Home
- VIR vs ECC Comparison
VIR vs ECC Comparison
Compare VIR & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- ECC
- Stock Information
- Founded
- VIR 2016
- ECC 2014
- Country
- VIR United States
- ECC United States
- Employees
- VIR N/A
- ECC N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- ECC
- Sector
- VIR Health Care
- ECC
- Exchange
- VIR Nasdaq
- ECC NYSE
- Market Cap
- VIR 844.9M
- ECC N/A
- IPO Year
- VIR 2019
- ECC N/A
- Fundamental
- Price
- VIR $5.41
- ECC $7.78
- Analyst Decision
- VIR Strong Buy
- ECC Buy
- Analyst Count
- VIR 7
- ECC 2
- Target Price
- VIR $32.86
- ECC $9.25
- AVG Volume (30 Days)
- VIR 1.1M
- ECC 1.2M
- Earning Date
- VIR 07-31-2025
- ECC 08-05-2025
- Dividend Yield
- VIR N/A
- ECC 24.71%
- EPS Growth
- VIR N/A
- ECC N/A
- EPS
- VIR N/A
- ECC N/A
- Revenue
- VIR $20,861,000.00
- ECC $191,298,536.00
- Revenue This Year
- VIR N/A
- ECC $26.00
- Revenue Next Year
- VIR N/A
- ECC $9.62
- P/E Ratio
- VIR N/A
- ECC N/A
- Revenue Growth
- VIR N/A
- ECC 29.29
- 52 Week Low
- VIR $4.32
- ECC $6.54
- 52 Week High
- VIR $14.45
- ECC $10.32
- Technical
- Relative Strength Index (RSI)
- VIR 55.40
- ECC 56.78
- Support Level
- VIR $4.91
- ECC $7.50
- Resistance Level
- VIR $5.35
- ECC $7.62
- Average True Range (ATR)
- VIR 0.25
- ECC 0.09
- MACD
- VIR 0.03
- ECC 0.03
- Stochastic Oscillator
- VIR 86.21
- ECC 87.18
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.